Previous 10 | Next 10 |
Atossa Therapeutics press release (NASDAQ:ATOS): Q1 GAAP EPS of -$0.04 beats by $0.02. As of March 31, 2022, the company had cash, cash equivalents and restricted cash of approximately $131,596. The company has no source of sustainable revenue and no associated cost of revenue. For further ...
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial...
SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and C...
The shares of Atossa Therapeutics (NASDAQ:ATOS) are trading higher for the first time in three sessions on Wednesday after the clinical-stage biotech announced it completed the enrollment in Part B of a Phase 1/2a clinical study for the experimental COVID-19 therapy, AT-H201. An inhalation fo...
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical s...
SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that management wil...
3 Hot Penny Stocks to Add to Your Watchlist in Mid-March When you are looking to invest in penny stocks, it is important to do your research first. Not all penny stocks are created equal, and some are much riskier than others. There are a few things to keep in mind when looking for pe...
Sunshine Biopharma (NASDAQ:SBFM) +201% on rising volume. American Rebel Holdings (NASDAQ:AREB) +28%. Bumble (NASDAQ:BMBL) +23% on Q4 results. Ecoark Holdings (NASDAQ:ZEST) +22% announces successful drilling of Louisiana oil well. Imperial Petroleum (NASDAQ:IMPP) ...
The U.S. Patent and Trademark Office has granted Atossa Therapeutics (ATOS) a key patent covering its breast cancer therapy candidate endoxifen. U.S. Patent No. 11,261,151 is titled “Methods for Making and Using Endoxifen.” In September, Atossa (ATOS) received approval in S...
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that the U.S. Paten...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...